Your browser doesn't support javascript.
loading
Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report / 부인종양
Journal of Gynecologic Oncology ; : 269-272, 2010.
Artículo en Inglés | WPRIM | ID: wpr-6889
ABSTRACT
Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Tamoxifeno / Mama / Neoplasias de la Mama / Adenofibroma / Neoplasias Endometriales / Toremifeno / Adenosarcoma / Medición de Riesgo Tipo de estudio: Estudio de etiología / Factores de riesgo Límite: Femenino / Humanos Idioma: Inglés Revista: Journal of Gynecologic Oncology Año: 2010 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Tamoxifeno / Mama / Neoplasias de la Mama / Adenofibroma / Neoplasias Endometriales / Toremifeno / Adenosarcoma / Medición de Riesgo Tipo de estudio: Estudio de etiología / Factores de riesgo Límite: Femenino / Humanos Idioma: Inglés Revista: Journal of Gynecologic Oncology Año: 2010 Tipo del documento: Artículo